1
|
Sandler A, Gray R, Perry MC, et al:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
|
2
|
Ciuleanu T, Brodowicz T, Zielinski C, et
al: Maintenance pemetrexed plus best supportive care versus placebo
plus best supportive care for non-small-cell lung cancer: a
randomised, double-blind, phase 3 study. Lancet. 374:1432–40. 2009.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Whithaus K, Fukuoka J, Prihoda TJ and
Jagirdar J: Evaluation of napsin A, cytokeratin 5/6, p63, and
thyroid transcription factor 1 in adenocarcinoma versus squamous
cell carcinoma of the lung. Arch Pathol Lab Med. 136:155–162. 2012.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Walker RA, Handy A, Pinder SE, et al:
Current issues in diagnostic breast pathology. J Clin Pathol.
65:771–785. 2012. View Article : Google Scholar : PubMed/NCBI
|
5
|
Slamon DJ, Godolphin W, Jones LA, et al:
Studies of the HER-2/neu proto-oncogene in human breast and ovarian
cancer. Science. 244:707–12. 1989. View Article : Google Scholar : PubMed/NCBI
|
6
|
Pennacchia I, Carbone A, Di Cerbo A, et
al: 2013 ASCO/CAP updated guidelines for human epidermal growth
factor receptor 2 testing: Impact on routine practice. Breast. Feb
19–2015.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
7
|
Yanagita E, Imagawa N, Ohbayashi C and
Itoh T: Rapid multiplex immunohistochemistry using the 4-antibody
cocktail YANA-4 in differentiating primary adenocarcinoma from
squamous cell carcinoma of the lung. Appl Immunohistochem Mol
Morphol. 19:509–513. 2011. View Article : Google Scholar : PubMed/NCBI
|
8
|
Ng WK, Chow JC and Ng PK: Thyroid
transcription factor-1 is highly sensitive and specific in
differentiating metastatic pulmonary from extrapulmonary
adenocarcinoma in effusion fluid cytology specimens. Cancer.
96:43–48. 2002. View Article : Google Scholar : PubMed/NCBI
|
9
|
Yatabe Y, Mitsudomi T and Takahashi T:
TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol.
26:767–773. 2002. View Article : Google Scholar : PubMed/NCBI
|
10
|
Ikeda S, Funakoshi N, Suzuki K, et al: A
study of double immunohistochemical staining for differential
diagnosis of adenocarcinoma and squamous cell carcinoma in
respiratory cytological smears. J Jpn Clin Cytol. 42:5–9. 2003.[(In
Japanese)]. View Article : Google Scholar
|
11
|
Hirano T, Auer G, Maeda M, et al: Human
tissue distribution of TA02, which is homologous with a new type of
aspartic proteinase, napsin A. Jpn J Cancer Res. 91:1015–1021.
2000. View Article : Google Scholar : PubMed/NCBI
|
12
|
Turner BM, Cagle PT, Sainz IM, et al:
Napsin A, a new marker for lung adenocarcinoma, is complementary
and more sensitive and specific than thyroid transcription factor 1
in the differential diagnosis of primary pulmonary carcinoma:
Evaluation of 1674 cases by tissue microarray. Arch Pathol Lab Med.
136:163–171. 2012. View Article : Google Scholar : PubMed/NCBI
|
13
|
Kakizaki Y, Nakagawa M, Honda T and Ishii
E: Immunohistochemical study using anti-Napsin A antibody for
primary lung adenocarcinoma. J Jpn Clin Cytol. 46:120–121.
2007.[(In Japanese)].
|
14
|
Shibuki Y, Tsuta K, Nomoto K, et al:
Immunocytochemical study of specific immunohistochemical markers
for primary lung adenocarcinoma: Surfactant apoprotein A, Napsin A,
Thyroid transcription factor-1. J Jpn Clin Cytol. 45:6–11.
2006.[(In Japanese)]. View Article : Google Scholar
|
15
|
Kim DH and Kwon MS: Role of fine needle
aspiration cytology, cell block preparation and CD63, P63 and CD56
immunostaining in classifying the specific tumor type of the lung.
Acta Cytol. 54:55–59. 2010. View Article : Google Scholar : PubMed/NCBI
|
16
|
Uke M, Rekhi B, Ajit D and Jambhekar NA:
The use of p63 as an effective immunomarker in the diagnosis of
pulmonary squamous cell carcinomas on de-stained bronchial lavage
cytological smears. Cytopathology. 21:56–63. 2010. View Article : Google Scholar : PubMed/NCBI
|
17
|
Aikawa E, Kawahara A, Hattori S, et al:
Comparison of the expression levels of napsin A, thyroid
transcription factor-1, and p63 in nonsmall cell lung cancer using
cytocentrifuged bronchial brushings. Cancer Cytopathol.
119:335–345. 2011. View Article : Google Scholar : PubMed/NCBI
|
18
|
Bishop JA, Teruya-Feldstein J, Westra WH,
et al: p40 (ΔNp63) is superior to p63 for the diagnosis of
pulmonary squamous cell carcinoma. Mod Pathol. 25:405–415. 2012.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Bhargava R, Beriwal S, McManus K and Dabbs
DJ: CK5 is more sensitive than CK5/6 in identifying the
‘basal-like’ phenotype of breast carcinoma. Am J Clin Pathol.
130:724–730. 2008. View Article : Google Scholar : PubMed/NCBI
|
20
|
Sethi S, Geng L, Shidham VB, et al: Dual
color multiplex TTF-1 + Napsin A and p63 + CK5 immunostaining for
subcategorizing of poorly differentiated pulmonary non-small
carcinomas into adenocarcinoma and squamous cell carcinoma in fine
needle aspiration specimens. Cytojournal. 9:102012. View Article : Google Scholar : PubMed/NCBI
|
21
|
Nonaka D: A study of ΔNp63 expression in
lung non-small cell carcinomas. Am J Surg Pathol. 36:895–9. 2012.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Li Y, Wang X, Ao M, et al: Aberrant
Mucin5B expression in lung adenocarcinomas detected by iTRAQ
labeling quantitative proteomics and immunohistochemistry. Clin
Proteomics. 10:152013. View Article : Google Scholar : PubMed/NCBI
|